

# UBS (CH) Institutional Fund – Equities Emerging Markets Asia I-A1

#### **Portrait**

- Regulation / Supervision: CISA / FINMA (Funds for qualified investors)
- Authorised investors: pension funds, insurance companies, family offices and institutional investors under CISA
- Investments: Equity securities issued by companies in Asian emerging markets
- No investments in securities on the recommendation list for exclusion of SVVK-ASIR (www.swk-asir.ch) and the UBS Asset Management Sustainability Exclusion Policy.
- Portfolio is actively managed and aims to outperform the benchmark
- Currency exposure: in line with securities portfolio
- Securities lending: permitted
- The fund valuation includes provisions for unrealised Indian capital gains taxes.
- Use of derivatives: permitted under BVV2
- All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

Securities no. ISIN		2,376,017 CH0023760173
		CH0023760173
Reuters symbol		LIDCENIA A CVA/
Bloomberg Ticker		UBSENAA SW
Currency of account		USD
Issue/redemption		daily
Admin/Custody fees		0.1800%
PM fees charged to the I	NAV	0.8000%
Swing pricing		yes
TER (as of 31.10.2023)		0.99%
Benchmark <sup>1)</sup>	MSCI Emerging M	arkets Asia (net div. reinv.)
1) Benchmark up to the 30.6.2007: MSCI Emerging Markets Asia (gross div.)		

# **Current data**

Net asset value 30.8.2024	USD	2,661.60
– high last 12 months	USD	2,855.49
– low last 12 months	USD	2,165.96
Assets of the unit class in m	USD	22.89
Fund assets in m	USD	455.45
Last distribution		reinvested

## Key risk figures (annualised)

	2 years	3 years
Tracking error	4.33%	3.88%
Beta	0.97	0.97
Correlation	0.98	0.98
Total risk	21.71%	18.79%
Sharpe ratio	0.05	-0.42
Risk-free rate (2 years) = 4.98%		
The statistical ratios were calculated on the basis of logarithmi	ic returns.	

#### Market exposure (in %)

	Fund	Benchmark
China	25.75	30.46
India	24.96	24.82
Republic of Korea	20.97	14.56
Taiwan	20.77	23.41
Indonesia	4.38	2.21
Malaysia	2.74	1.94
Cash	0.43	0.00
Philippines	0.00	0.73
Thailand	0.00	1.87
Total	100.00	100.00

#### Performance (in %)

	Fund	Benchmark
09.2023	-2.28	-2.59
10.2023	-2.88	-3.95
11.2023	9.43	7.59
12.2023	3.03	3.26
01.2024	-5.16	-5.22
02.2024	5.40	5.85
03.2024	3.65	2.66
04.2024	0.77	1.28
05.2024	1.83	1.42
06.2024	6.42	4.96
07.2024	-3.45	-0.28
08.2024	-0.19	1.63
2024 YTD	9.03	12.54
2023	9.09	7.76
2022	-23.84	-21.11
2021	-8.91	-5.08
2020	33.05	28.38
2019	28.36	19.24
Ø p.a. 2 years	6.15	7.99
Ø p.a. 3 years since end of fund launch month	-4.37	-3.16
09.2006	159.19	137.84

#### Indexed performance



UBS (CH) Institutional Fund – Equities Emerging Markets Asia I-A1
MSCI Emerging Markets Asia (net div. reinv.)

Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

### 10 largest positions according to issuers (in %)

	Fund	Benchmark
TAIWAN SEMICONDUCTOR MANUFAC	9.85	11.86
TENCENT HOLDINGS LTD	9.47	5.28
SAMSUNG ELECTRONICS KRW5000	8.96	4.93
HDFC BANK LIMITED	4.68	0.89
MEDIATEK INC TWD10	4.10	0.96
Top 5	37.06	23.92
SK HYNIX INC	3.90	1.16
EICHER MOTORS LTD	3.82	0.13
AXIS BANK LTD	3.63	0.52
ASE TECHNOLOGY HOLDING CO LT	3.35	0.26
PINDUODUO INC ADR	2.81	0.94
Top 10	54.57	26.93

# UBS (CH) Institutional Fund – Equities Emerging Markets Asia I-A1

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus, and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency of a financial product or financial service is different from your reference currency, the r

Additional information to investors in specific countries: Switzerland: Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.